X hits on this document

Word document

NATIONAL HIV/AIDS RESEARCH AND BEST PRACTICES CONFERENCE - page 57 / 103

255 views

0 shares

0 downloads

0 comments

57 / 103

B9. THE OCCURRENCE OF POTENTIALLY SERIOUS TOXICITIES TO NEVIRAPINE AND ZIDOVUDINE IN HIV-INFECTED, POST-PARTUM WOMEN WITH HIGH CD4 COUNTS, AND IN THEIR HIV-UNINFECTED INFANTS.

Bramson B1, Chasela C1, Ahmed Y2, Hosseinipour M1 Kourtis A2, Martinson F1, Kazembe P3,  Hoffman I1, Jamieson D2, van der Horst C1

1UNC Project, Lilongwe, Malawi; 2Centers for Disease Control, Atlanta, USA; 3Kamuzu Central Hospital

Objective: We describe the occurrence of potentially serious toxicities to nevirapine and zidovudine when given to breastfeeding women with high CD4 counts or their HIV-uninfected infants in a breastfeeding transmission prevention trial in Malawi.

Methods: The Breastfeeding Antiretroviral Nutrition Study (BAN) is a prospective randomized controlled factorial clinical trial of an antiretroviral and a nutritional intervention interventional trial. In addition to peripartum prophylaxis, mother-infant pairs are randomly assigned at birth  to one of three groups: 1) maternal zidovudine/lamivudine/nevirapine for 28 weeks, , 2) daily infantnevirpine for 28 weeks, or 3) no additional prophylaxis.  HIV- infected pregnant women with baseline CD4 counts >200 cells/microliter are eligible for randomization.    All enrolled subjects were assessed regularly for signs, symptoms, or laboratory values suggesting anti-retroviral drug toxicities, with pre-determined criteria for changing or discontinuing ARV treatment in response to toxicities.

Results: From 24 April 2004 through 31 January 2005, thirty-eight were randomized to receive maternal anti-retroviral drugs and thirty-seven infants were randomized to receive daily nevirapine.One woman was discontinued in the first week due to inability to breastfeed.  Of the remaining 37 women, 8 (21.6%) were changed from nevirapine to nelfinavir in response to cutaneous or hepatic toxicities. Five of 37 women (13.5%) were changed from zidovudine to stavudine in response to anemia and neutropenia.  One infant of 37 (2.7%) receiving nevirapine was switched to nelfinavir for possible hepatomegaly.  

Conclusions: When nevirapine is used in post-partum women with CD4 counts > 200 cells/microliter, women should be monitored closely for cutaneous and hepatic toxicities.  In addition, when zidovudine is used in this population, women should be monitored closely for hematologic toxicicties.

Recommendations: Nevirapine should be used cautiously in women with high CD4 cell counts and if given, requires close clinical monitoring.  The use of zidovudine requires laboratory monitoring.

Document info
Document views255
Page views255
Page last viewedThu Dec 08 15:04:42 UTC 2016
Pages103
Paragraphs1147
Words29940

Comments